Laboratory analysis of the antibody-based Covid-19 therapy GlaxoSmithKline is developing with U.S. partner Vir Biotechnology indicated the drug is effective against the new Omicron variant, the British drugmaker said on December 2.
If you are not happy with the results below please do another search
50 search results for:
The Ashfield Health mantra is make it matter. According to management, this is more than a phrase—it’s a powerful purpose. On November 12th, Ashfield Health set out to make a difference as 1,500 people from 7 agencies, across 7 countries came together to make a positive impact on their communities.
Fears over the impact of the Omicron variant of the coronavirus rose on Thursday after the first case was reported in the United States and the Japanese central bank warned of economic pain as countries respond with tighter containment measures.
Bristol Myers Squibb Co. was sued on December 1 by four employees who said the drugmaker refused to grant them religious exemptions from the company’s Covid-19 vaccination requirement, and threatened to fire them on Dec. 6 for remaining unvaccinated.
U.S. President Joe Biden on December 1 unveiled an updated national strategy to combat the AIDS epidemic by boosting money for research, increasing access to treatment, and recognizing the role racism plays in inequitable access to medical services.
The first U.S. case of the Omicron variant of COVID-19 was detected in California, top U.S. infectious disease expert Anthony Fauci said on December 1.
Moderna Inc. could face a patent infringement lawsuit over the company’s COVID-19 vaccine after a federal appeals court on December 1 rejected its challenge to patents belonging to Arbutus Biopharma Corp.
Almost one year after Biogen forged a collaboration with Sage Therapeutics worth $1.52 billion, the development deal for the experimental major depressive disorder treatment zuranolone is bearing fruit that will support an expected rolling New Drug Application during 2022.
Moderna Inc. could have a COVID-19 booster shot targeting the Omicron variant tested and ready to file for U.S. authorization as soon as March 2022, the company’s president said on December 1.
Janssen Pharmaceutical and Amgen received another regulatory win for Darzalex Faspro (daratumumab and hyaluronidase-fihj) as the U.S. Food and Drug Administration approved the drug in combination with Amgen’s Kyprolis (carfilzomib) and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.